Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
06:59am, Monday, 25'th Aug 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025.
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
12:16pm, Friday, 22'nd Aug 2025
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
Final Trades: ServiceNow, Bristol Myers and Live Nation
02:20pm, Thursday, 21'st Aug 2025
The Investment Committee give you their top stocks to watch for the second half.
5 Strong-Buy Stocks With Hard-to-Find 5% and Higher Yields
08:19am, Thursday, 21'st Aug 2025
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream and offer a promising avenue for total return.
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
10:56am, Wednesday, 20'th Aug 2025
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
10:01am, Tuesday, 19'th Aug 2025
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01
Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends
08:45am, Thursday, 14'th Aug 2025
The Dividend Harvesting Portfolio rebounded strongly, with profitability up 8.06% and total dividend income now at 19.77% of invested capital. I remain bullish on the S&P 500 reaching 7,000 this year,
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
09:40am, Wednesday, 13'th Aug 2025
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks
06:26am, Wednesday, 13'th Aug 2025
Investing in high-yielding dividend stocks can result in significant dividend income for your portfolio. But higher yields also tend to mean higher risk, and dividends are never guaranteed.
3 SWANs On Sale
07:00am, Friday, 08'th Aug 2025
Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a li
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
10:21am, Wednesday, 06'th Aug 2025
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 05'th Aug 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
10:53pm, Monday, 04'th Aug 2025
Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focused
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's Application for Breyanzi Accepted by U.S. FDA in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL).
